TRC253
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for TRC253, covering 2021-04-23 to 2021-04-23. Get the full timeline:
Most recent: Clinical Trial Update: Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients [Phase 1, Phase 2]